The primary focus is on the company’s bexotegrast, an αvß6/αvß1 integrin inhibitor, which is being developed for the treatment of idiopathic pulmonary fibrosis (IPF). The enrollment for the Phase 2b/3 ...

TCGFB, a private biotech founded by healthcare VC The Column Group, is tapping California biotech Surrozen to discover ...

Idiopathic pulmonary fibrosis (IPF) is characterized by a progressive decline in lung function, worsening quality of life, and high mortality. However, the rate and pattern of progression of IPF ...

The asset at play is fipaxalparant, a candidate designed to block the lysophosphatidic acid receptor 1 (LPAR1). Amgen tested ...

Pliant Therapeutics (PLRX – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Ed ...

A recent study showed that the COPD assessment test was reliable and responsive for assessing health status in fibrotic ...

Identifying the underlying causes of prolonged lung inflammation associated with radiographic abnormalities could be key understanding long COVID and other lung conditions, researchers say.

Idiopathic pulmonary fibrosis (IPF) is a debilitating idiopathic lung disease that leads to early death. There are no effective medical therapies for IPF. Recent discoveries have identified a ...

These compelling results support advancing the development of nintedanib DPI for patients living with IPF, a chronic and progressive fibrotic lung disease with limited treatment options,” said Michael ...

Columnist Sam Kirton is doing a service for him and his family's future generations by sharing his research on the family ...

Surrozen, Inc. (“Surrozen” or the “Company”) (Nasdaq: SRZN), a company pioneering targeted therapeutics that selectively activate the Wnt pathway for tissue repair and regeneration, today announced a ...